Skip to main content
SpringerLink
Log in

New Insights into Plaque Stabilisation by Lipid Lowering

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Thrombosis on the substrate of a disrupted plaque causes most acute coronary events. The physical integrity of the plaque thus governs the most important clinical manifestations of atherosclerosis. Of particular importance is the extracellular matrix of the fibrous capsule overlying the thrombogenic core of the atheroma.

Stable atheroma generally have thick fibrous caps, and smaller lipid cores than lesions that have ruptured. Accumulating evidence supports a key role for inflammation as another critical determinant of the stability of human atherosclerotic plaques.

Plaques that rupture usually have more abundant leucocytic infiltrates than those considered stable. Inflammatory mediators such as cytokines can influence several biological processes that regulate the stability of the plaque's fibrous cap, and thus its resistance to rupture.

For example, interferon-γ produced by activated T lymphocytes within atheroma inhibits the production of interstitial forms of collagen by human vascular smooth muscle cells. Inflammatory cytokines such as interleukin-1, tumour necrosis factor (TNF) and CD-40 ligand (a cell surface homologue of TNFα) can also elicit the expression by macrophages and smooth muscle cells of proteolytic enzymes that can weaken the extracellular matrix.

We have hypothesised that lipid lowering reduces stimuli for the inflammatory response within the complex atherosclerotic lesion. Recent studies in rabbits with experimentally produced atherosclerosis have indeed shown that lipid lowering can (i) reduce macrophage numbers, (ii) decrease expression of the collagenolytic enzyme MMP-1, and (iii) reinforce the plaque's fibrous skeleton by increasing the content of interstitial collagen.

By reducing local inflammation, lipid lowering can thus stabilise the plaque's fibrous cap, rendering the atheroma less prone to rupture and to precipitate thrombotic complications.

These observations provide a mechanistic basis for understanding the marked reduction in acute coronary events and cerebrovascular accidents observed in patients treated with agents that reduce plasma lipids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smith SC. Risk-reduction therapy: the challenge to change. Presented at the 68th scientific sessions of the American Heart Association; 1995 Nov 13: Anaheim, California. Circulation 1996; 93: 2205–11

    Google Scholar 

  2. Topol EJ, Nissen SE. Our preoccupation with coronary luminology: the dissociation between clinical and angiographie findings in ischemic heart disease. Circulation 1995; 92: 2333–42

    Article  PubMed  CAS  Google Scholar 

  3. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Card 1995; 28: 1133–9

    Article  Google Scholar 

  4. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528–40

    Article  PubMed  CAS  Google Scholar 

  5. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscleros Thromb 1994; 14: 177–92

    CAS  Google Scholar 

  6. Waters D, Higginson L, Gladstone P. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959–68

    CAS  Google Scholar 

  7. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. New Eng J Med 1997; 336: 153–62

    Article  Google Scholar 

  8. Oliver MF, de Feyter PJ, Lubeen J. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–8

    Article  Google Scholar 

  9. Herd JA, Ballantyne CM, Fanner JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study). Am J Card 1997; 80: 278–86

    Article  PubMed  CAS  Google Scholar 

  10. Brown BG, Zhao X-Q, Sacco DE, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781–91

    Article  PubMed  CAS  Google Scholar 

  11. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sc U S A 1989; 86: 2839–43

    Article  CAS  Google Scholar 

  12. Libby P. The molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–50

    Article  PubMed  CAS  Google Scholar 

  13. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–71

    Article  PubMed  CAS  Google Scholar 

  14. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation 1996; 94: 2013–20

    Article  PubMed  CAS  Google Scholar 

  15. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution onfissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941–4

    Article  PubMed  CAS  Google Scholar 

  16. Loree HM, Kamm RD, Stringfellow RG, et al. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992; 71: 850–8

    Article  PubMed  CAS  Google Scholar 

  17. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994; 90: 775–8

    Article  PubMed  CAS  Google Scholar 

  18. Amento EP, Ehsani N, Palmer H, et al. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscleros Thromb 1991; 11: 1223–30

    Article  CAS  Google Scholar 

  19. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169–75

    PubMed  CAS  Google Scholar 

  20. van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36–44

    Article  PubMed  Google Scholar 

  21. Hansson GK, Jonasson L, Holm J, et al. Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ Res 1988; 63: 712–9

    Article  PubMed  CAS  Google Scholar 

  22. Warner SJC, Friedman GB, Libby P. Immune interferon inhibits proliferation and induces 2′-5′-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J Clin Invest 1989; 83: 1174–82

    Article  PubMed  CAS  Google Scholar 

  23. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1585–9

    Google Scholar 

  24. Galis ZS, Sukhova GK, Kranzhofer R, et al. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995; 92: 402–6

    Article  PubMed  CAS  Google Scholar 

  25. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995; 9: 974–80

    PubMed  CAS  Google Scholar 

  26. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaque by in situ hybridization. Proc Natl Acad Sci U S A 1991; 88: 8154–8

    Article  PubMed  CAS  Google Scholar 

  27. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extra cellular matrix digestion. Circ Res 1994; 75: 181–9

    Article  PubMed  CAS  Google Scholar 

  28. Saren P, Welgus HG, Kovanen PT. TNF-α and IL-1β selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996; 157: 4159–65

    PubMed  CAS  Google Scholar 

  29. Mach F, Schönbeck U, Bonnefoy J-Y, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin and tissue factor. Circulation 1997; 96: 396–9

    Article  PubMed  CAS  Google Scholar 

  30. Kaplan JR, Manuck SB, Adams MR, et al. Plaque changes and aeterial enlargement in atherosclerotic monkeys after manipulation of diet and social environment. Arterioscler Thromb 1993; 13: 254–63

    Article  PubMed  CAS  Google Scholar 

  31. Shiomi M, Koh T, Tsudaka T, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Aterioscleros Thromb Vasc Biol 1995; 15: 1938–44

    Article  CAS  Google Scholar 

  32. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97: 2433–44

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Medicine, Brigham & Women's Hospital, Harvard Medical School, 221 Longwood Avenue, LMRC 307, Boston, Massachusetts, 02115, USA

    Peter Libby (Chief) & Masanori Aikawa

Authors
  1. Peter Libby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masanori Aikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Libby, P., Aikawa, M. New Insights into Plaque Stabilisation by Lipid Lowering. Drugs 56 (Suppl 1), 9–13 (1998). https://doi.org/10.2165/00003495-199856001-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199856001-00002

Keywords

Search

Navigation